169 related articles for article (PubMed ID: 26937887)
1. Pitfalls in [¹⁸F]FDG PET imaging in gynecological malignancies.
Hernandez Pampaloni M; Facchetti L; Nardo L
Q J Nucl Med Mol Imaging; 2016 Jun; 60(2):124-38. PubMed ID: 26937887
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography-computed tomography imaging for malignancies in women.
Viswanathan C; Bhosale PR; Shah SN; Vikram R
Radiol Clin North Am; 2013 Nov; 51(6):1111-25. PubMed ID: 24210447
[TBL] [Abstract][Full Text] [Related]
3. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
4. Normal Variants and Pitfalls Encountered in PET Assessment of Gynecologic Malignancies.
Yu JQ; Doss M; Alpaugh RK
PET Clin; 2018 Apr; 13(2):249-268. PubMed ID: 29482753
[TBL] [Abstract][Full Text] [Related]
5. FDG PET/CT in monitoring response to treatment in gynecological malignancies.
Amit A; Person O; Keidar Z
Curr Opin Obstet Gynecol; 2013 Feb; 25(1):17-22. PubMed ID: 23299090
[TBL] [Abstract][Full Text] [Related]
6. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer.
Xin J; Ma Q; Guo Q; Sun H; Zhang S; Liu C; Zhai W
Eur J Radiol; 2016 Apr; 85(4):751-9. PubMed ID: 26971419
[TBL] [Abstract][Full Text] [Related]
7. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
8. Gynecologic oncologic imaging with PET/CT.
Grant P; Sakellis C; Jacene HA
Semin Nucl Med; 2014; 44(6):461-78. PubMed ID: 25362236
[TBL] [Abstract][Full Text] [Related]
9. FDG PET-CT of gynecologic cancers: pearls and pitfalls.
Prabhakar HB; Kraeft JJ; Schorge JO; Scott JA; Lee SI
Abdom Imaging; 2015 Oct; 40(7):2472-85. PubMed ID: 25680500
[TBL] [Abstract][Full Text] [Related]
10. Imaging of gynecologic malignancies with FDG PET-CT: case examples, physiologic activity, and pitfalls.
De Gaetano AM; Calcagni ML; Rufini V; Valentini AL; Gui B; Giordano A; Bonomo L
Abdom Imaging; 2009 Nov; 34(6):696-711. PubMed ID: 18791682
[TBL] [Abstract][Full Text] [Related]
11. FDG PET/CT Pitfalls in Gynecologic and Genitourinary Oncologic Imaging.
Lakhani A; Khan SR; Bharwani N; Stewart V; Rockall AG; Khan S; Barwick TD
Radiographics; 2017; 37(2):577-594. PubMed ID: 28287942
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET Assessment of Other Gynecologic Cancers.
Faria S; Devine C; Viswanathan C; Javadi S; Korivi BR; Bhosale PR
PET Clin; 2018 Apr; 13(2):203-223. PubMed ID: 29482750
[TBL] [Abstract][Full Text] [Related]
13. Integrated whole-body PET/MR hybrid imaging: clinical experience.
Quick HH; von Gall C; Zeilinger M; Wiesmüller M; Braun H; Ziegler S; Kuwert T; Uder M; Dörfler A; Kalender WA; Lell M
Invest Radiol; 2013 May; 48(5):280-9. PubMed ID: 23442775
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous positron emission tomography/magnetic resonance imaging for whole-body staging in patients with recurrent gynecological malignancies of the pelvis: a comparison to whole-body magnetic resonance imaging alone.
Grueneisen J; Beiderwellen K; Heusch P; Gratz M; Schulze-Hagen A; Heubner M; Kinner S; Forsting M; Lauenstein T; Ruhlmann V; Umutlu L
Invest Radiol; 2014 Dec; 49(12):808-15. PubMed ID: 25010207
[TBL] [Abstract][Full Text] [Related]
15. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed?
Kuhn FP; Hüllner M; Mader CE; Kastrinidis N; Huber GF; von Schulthess GK; Kollias S; Veit-Haibach P
J Nucl Med; 2014 Apr; 55(4):551-8. PubMed ID: 24491410
[TBL] [Abstract][Full Text] [Related]
16. Gynecological cancers.
Avril N; Gourtsoyianni S; Reznek R
Methods Mol Biol; 2011; 727():171-89. PubMed ID: 21331934
[TBL] [Abstract][Full Text] [Related]
17. A Role of PET Agents Beyond FDG in Gynecology.
Ponisio MR; Dehdashti F
Semin Nucl Med; 2019 Nov; 49(6):501-511. PubMed ID: 31630734
[TBL] [Abstract][Full Text] [Related]
18. What's New in Imaging for Gynecologic Cancer?
Khan SR; Arshad M; Wallitt K; Stewart V; Bharwani N; Barwick TD
Curr Oncol Rep; 2017 Nov; 19(12):85. PubMed ID: 29105030
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of PET-CT pelvic pitfalls in patients with gynecologic malignancies.
Gorospe L; Jover-Díaz R; Vicente-Bártulos A
Abdom Imaging; 2012 Dec; 37(6):1041-65. PubMed ID: 22349805
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography in gynecologic cancer.
Yen TC; Lai CH
Semin Nucl Med; 2006 Jan; 36(1):93-104. PubMed ID: 16356798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
